AAOS Comments on Request for Information for Episode-Based Payment Model

Last week the American Association of Orthopaedic Surgeons (AAOS) submitted comments to the Center for Medicare and Medicaid Innovation (CMMI) in response to a request for information they released in July regarding the development of Episode-Based Payment Models (CMS-5540-NC).

In its letter, AAOS expressed their support for engaging physicians in the design and implementation of alternative payment models and urged the Centers for Medicare & Medicaid Services (CMS) to consider the impact that interoperability, multi-payer alignment of measures, and administrative burden have on the ability of physicians to successfully participate in alternative payment models.

As a thought leader in reducing the complexities of value-based care and as clinical experts delivering high-value, patient-centered musculoskeletal care, AAOS shared their insights and recommendations which include:

Expanding alternative payment model (APM) episodes beyond 30 days, and encouraging the agency to consider episodes longer than 90 days
Only considering voluntary models with participation incentives– as a mandatory model would be in the disinterest of collaborative, patient-centered care
Ensuring that barriers, such as interoperability, multi-payer alignment of measures, and administrative burden are resolved in future models
Finding an approach that allows downstream risk sharing with orthopaedic surgeons
Exploring a pilot program for the management of chronic and prevalent conditions by orthopaedic surgeons

In July, AAOS and several physician organizations, requested an extension to the proposal’s 30-day comment period. While the request was denied by CMMI, the agency agreed to meet with AAOS for further discussions.

“The AAOS is excited to partner with CMS and offer our expertise based on our extensive experience with the design, implementation, and evaluation of value-based payment models. As leaders in payment model transformation, the AAOS is well-positioned to ensure that changes to the way hospitals and physicians are paid for their services ultimately provides value to Medicare beneficiaries and their families, while reducing the administrative burden on the healthcare system,” wrote AAOS President Kevin J. Bozic, MD, MBA, FAAOS.

Read the full letter here.

 

 

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.